| __timestamp | Amphastar Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 855506000 |
| Thursday, January 1, 2015 | 37065000 | 996170000 |
| Friday, January 1, 2016 | 41199000 | 1047690000 |
| Sunday, January 1, 2017 | 43415000 | 1324625000 |
| Monday, January 1, 2018 | 57564000 | 1416476000 |
| Tuesday, January 1, 2019 | 68853000 | 1754540000 |
| Wednesday, January 1, 2020 | 67229000 | 1829537000 |
| Friday, January 1, 2021 | 60932000 | 3051100000 |
| Saturday, January 1, 2022 | 74771000 | 2540300000 |
| Sunday, January 1, 2023 | 73741000 | 3162900000 |
| Monday, January 1, 2024 | 3630300000 |
Unleashing insights
In the competitive world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Vertex Pharmaceuticals Incorporated has consistently outpaced Amphastar Pharmaceuticals, Inc. in R&D investment. From 2014 to 2023, Vertex's R&D expenses surged by an impressive 270%, peaking at approximately $3.16 billion in 2023. In contrast, Amphastar's R&D spending grew by a modest 160%, reaching around $73 million in the same year.
This stark difference highlights Vertex's aggressive strategy to maintain its leadership in the biotech sector, focusing on groundbreaking treatments. Meanwhile, Amphastar's steady growth reflects its commitment to incremental innovation. As the pharmaceutical landscape evolves, these investment trends underscore the varying approaches companies take to drive future growth and innovation.
Research and Development Investment: Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and Exelixis, Inc.
Research and Development Expenses Breakdown: Vertex Pharmaceuticals Incorporated vs Viking Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Comparing Innovation Spending: Sarepta Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: Opthea Limited vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. or MannKind Corporation: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Amphastar Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.
R&D Insights: How Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. Allocate Funds